ar-9281
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2009 (NCT00847899)
Timeline
2000s
- Jan 1, 2009
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Epoxide hydrataseINHIBITOR
EPHX2 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- 1-(1-acetyl-piperidine-4-yl)-3-adamantan-1-yl-urea
- ar9281
- ar9281
- ar9281
- ar 9281
- ar-9281
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00847899 | Phase 2 | Jan 1, 2009 | Arete Therapeutics |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Arete Therapeutics | For profit | 1 | 1 | 1 | 2009 |
1 organizations
Page 1 / 1